Lincoln Pharmaceuticals to start making hydroxychloroquine
Gets Gujarat FDCA nod for the drug and its variants in different dosages27-04-2020
27-04-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Lincoln Pharmaceuticals Limited receives approval to manufacture Hydroxychloroquine and Hydroxychloroquine Sulfate Tablets to fight COVID 19.27-04-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Shareholding for the Period Ended March 31, 2020
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here21-04-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015-Updates
Update on impact of Novel Coronavirus (COVID-19)09-04-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation for Change in authorised Key Managerial Personnel for the purpose of determining Materiality of events.03-04-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Clarification
With reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded, Lincoln Pharmaceuticals Ltd has submitted to BSE a copy of Clarification is enclosed.03-04-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Clarification sought from Lincoln Pharmaceuticals Ltd
The Exchange has sought clarification from Lincoln Pharmaceuticals Ltd on 01st April, 2020 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.01-04-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Closure of Trading Window
Intimation of closure of Trading Window.31-03-2020
LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Karnavati Distributors Ltd & PACs20-03-2020
Lincoln Pharmaceuticals Ltd - 531633 - Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajnikant Gulabdas Patel17-03-2020